Pfizer Inc. Q1 FY2026 Earnings Call Summary
PFE
NYSE
Healthcare
📅 2026-05-05
⏱ ~60 sec read
🟡 Neutral
⏱️ 60-Second Brief
Pfizer Inc. · Q1 FY2026
Revenue
$14.5B
EPS
$0.47
AI Sentiment
🟡 Neutral
The company's strong performance in new and acquired product…
📌 Bottom Line:
Pfizer delivered a strong first quarter in 2026, with revenues reaching $14.5 billion and adjusted diluted EPS of $0.75, driven by robust growth in its launched and acquired product portfolio. The company reaffirmed its …
🤖 AI-Assisted Summary — Produced using a custom AI pipeline by Abhi, reviewed for accuracy.
·
⚠️ Not financial advice. For informational purposes only.
Full Disclaimer →
📋 TL;DR — What Happened
Pfizer delivered a strong first quarter in 2026, with revenues reaching $14.5 billion and adjusted diluted EPS of $0.75, driven by robust growth in its launched and acquired product portfolio. The company reaffirmed its full-year financial guidance, signaling confidence in its strategic pivot despite a significant decline in COVID-19 product sales.
📊 Key Financial Metrics
Revenue
$14.5B
EPS (Diluted)
$0.47
YoY Revenue Growth
2%
Gross Margin
75.4%
Net Income
$2.687B
AI Sentiment
🟡 Neutral
The company's strong performance in new and acquired products and robust pipeline progress are balanced by the significant decline in COVID-19 product revenues, leading to a mixed financial picture.
✅ What Went Well
The portfolio of recently launched and acquired products delivered an impressive 22% operational revenue growth, demonstrating Pfizer's successful strategy in bringing new, high-value medicines to market and integrating strategic acquisitions. Key contributors included Padcev (up 39% operationally), Oncology biosimilars (up 52% operationally), and Nurtec ODT/Vydura (up 41% operationally).
Pfizer showcased strong R&D momentum with positive Phase 3 results for Elrexfio in multiple myeloma, Braftovi in metastatic colorectal cancer, and Talzenna in prostate cancer, alongside promising Phase 2 data for atirmociclib in breast cancer and tilrekimig in atopic dermatitis. The CEO specifically highlighted encouraging progress in oncology and obesity, positioning Pfizer for future leadership in these critical therapeutic areas.
The company secured crucial patent settlement agreements for Vyndamax, extending its U.S. patent expiry to June 1, 2031. This strategic legal victory is projected to maintain revenue stability for Vyndamax from 2028 through mid-2031, providing a longer runway for a key product and enhancing predictability for investors.
⚠️ Concerns & Risks
The most significant headwind was the dramatic drop in sales for Pfizer's COVID-19 products. Comirnaty revenues plummeted 59% operationally, and Paxlovid revenues fell 63% operationally, primarily due to lower demand, reduced government purchases, and narrower vaccination recommendations. This substantial decline continues to exert pressure on overall revenue growth.
Despite overall revenue growth, reported net income attributable to Pfizer Inc. common shareholders decreased by 9% to $2.687 billion, and reported diluted EPS declined by 10% to $0.47 compared to the prior-year quarter. This indicates that while sales are growing in certain areas, profitability on a GAAP basis faced challenges, partly due to higher cost of sales and an unfavorable tax rate.
The cost of sales as a percentage of revenues increased by 3.8 percentage points, resulting in a reported gross margin of 75.4%, primarily due to the non-recurrence of a favorable royalty estimate revision from the prior year and an unfavorable impact of foreign exchange. Additionally, the effective tax rate on reported income increased significantly to 14.6% from (6.8)% in the prior year, driven by an unfavorable jurisdictional mix of earnings and the non-recurrence of favorable global income tax resolutions, impacting net profitability.
🔮 CEO / Management Guidance
Pfizer's management reaffirmed its full-year 2026 financial guidance, projecting total revenues to be in the range of $59.5 billion to $62.5 billion. They also maintained their adjusted diluted EPS outlook between $2.80 and $3.00, indicating confidence in the company's ability to execute its strategy and deliver on its financial targets for the remainder of the year, despite ongoing market dynamics.
💬 Key Quote
We're off to a strong start in 2026, and it reinforces our confidence that we will successfully navigate this defining period for Pfizer. Our R&D pipeline is advancing on multiple fronts – with positive Phase 3 readouts and encouraging mid-stage results building meaningful momentum – and I'm particularly encouraged by what we're seeing in oncology and obesity, two areas where I believe Pfizer is positioned to lead. — Dr. Albert Bourla, Chairman and CEO
📅 Quarter-over-Quarter Comparison
Comparing Q1 FY2026
vs Q4 FY2026
All quarters →
Revenue
$62.6B
→
$14.5B
EPS
$0.66
→
$0.47
Sentiment
🟡 Neutral
→
🟡 Neutral
🏢 About Pfizer Inc.
Pfizer Inc. (PFE) is a publicly listed company on the NYSE exchange in the Healthcare sector. EarningsBloom tracks its quarterly earnings calls to provide free AI-generated summaries for investors.
📈 Want to act on this insight?
Topics:
Pharmaceuticals
Biotechnology
Oncology
Drug Development
📁 More from Pfizer Inc.
View all earnings summaries for Pfizer Inc. →